Acute migraine therapy: recent evidence from randomized comparative trials

  title={Acute migraine therapy: recent evidence from randomized comparative trials},
  author={Anna Mett and Peer Tfelt-Hansen},
  journal={Current Opinion in Neurology},
(1) A wide array of data regarding acute migraine treatment are available, but few trials strictly adhere to International Headache Society guidelines for patient inclusion criteria.(2) Triptans appear to have similar efficacy profiles, but among newer triptans, almotriptan offers improved tolerability over sumatriptan.(3) Combination indomethacin/caffeine/prochlorperazine most likely has similar therapeutic efficacy to triptan therapy, with further research needed to complete understanding of… 
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Aspirin 1000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 mg or 100 mg, and addition of metoclopramide 10 mg improves relief of nausea and vomiting.
Triptans for the Management of Migraine
Evaluated dosing can offer increased efficacy but may confer a higher risk of adverse events, which are usually mild to moderate and transient in nature.
Acute treatment of migraine headaches.
  • F. Taylor
  • Medicine, Psychology
    Seminars in neurology
  • 2010
Clinicians should utilize evidence-based acute migraine-specific therapy stressing the imperative acute treatment goal of early intervention, but not too often with the correct drug, formulation, and dose.
Ibuprofen with or without an antiemetic for acute migraine headaches in adults.
Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.
Are the current IHS guidelines for migraine drug trials being followed?
A systematic review of published controlled trials of drugs in migraine from 2002 to 2008 found that adherence to international guidelines like these of IHS is important to ensure that only high-quality trials are performed, and to provide the consensus that is required for meta analyses.
A review of frovatriptan for the treatment of menstrual migraine
  • E. MacGregor
  • Medicine
    International journal of women's health
  • 2014
Frovatriptan is supported as a first-line acute treatment for MM and for perimenstrual prophylaxis and post hoc analyses from randomized trials of MM show similar pain relief and pain-free rates for frov atriptan compared with other triptans.
Diagnostics and modern treatment of migraine: what can a general practitioner do?
  • V. Osipova
  • Psychology, Medicine
    Medical alphabet
  • 2021
The article focuses on the basic principles of diagnosis and treatment of migraine at the stage of primary health care, and the advantages of eletriptan as a last‑generation triptan, which is highly effective in relieving migraine attacks and is safer than other drugs in this class.
Italian guidelines for primary headaches: 2012 revised version
The first edition of the Italian diagnostic and therapeutic guidelines for primary headaches in adults was published in J Headache Pain 2(Suppl. 1):105–190 in 2001 and a section was dedicated to non-pharmacological treatment.
Development and Evalaution of a New Combined Dosage form for Migraine.
The fourth chapter deals with the materials and methods used and the experimental procedures adopted and describes in detail the procedure adopted for the optimization of the fixed dosage combination form by preformulation and formulation studies.


Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Sumatriptan, 85 mg, plus naproxen sodium, 500 mg, as a single tablet for acute treatment of migraine resulted in more favorable clinical benefits compared with either monotherapy, with an acceptable and well-tolerated adverse effect profile.
Efficacy of oral ketoprofen in acute migraine: A double-blind randomized clinical trial
Oral ketoprofen (75 mg or 150 mg) in a dual-release formulation is an effective and well-tolerated drug in the acute treatment of migraine attacks.
Almotriptan is an Effective and Well-Tolerated Treatment for Migraine Pain: Results of A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
The results from this large clinical study indicate that the new, specific 5-HT1B/1D agonist, almotriptan, is an effective and well-tolerated treatment for migraine pain.
Ergotamine in the acute treatment of migraine: a review and European consensus.
Ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions.
EFNS guideline on the drug treatment of migraine – report of an EFNS task force
To give evidence‐based or expert recommendations for the different drug treatment procedures of the different migraine syndromes based on a literature search and an consensus in an expert panel, the recommendations of the EFNS are given.
Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
This randomised trial shows that oral eletriptan is more efficacious in the acute treatment of migraine than oral Cafergot and is well tolerated.
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
Almotriptan and sumatriptan are similarly effective in the abortive treatment of moderate or severe migraine headache; they are also similarly well tolerated and safe.
Crossover, double‐blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy
Almotriptan was associated with significantly greater efficacy for treating migraine compared with ergotamine plus caffeine, was generally well tolerated and was associatedWith greater rate of treatment satisfaction.
Migraine: pathophysiology, pharmacology, treatment and future trends.
Although the triptans are effective antimigraine agents producing selective cranial vasoconstriction, efforts are being made to develop other effective antimIGraine alternatives acting via the direct blockade of vasodilator mechanisms (e.g. antagonists at CGRP receptors, antagonists at 5-HT7 receptors, inhibitors of nitric oxide biosynthesis, etc).